Day One Shares Up 36% Premarket After Co On Sunday Announced Overall Response Rate Of 67% And Clinical Benefit Rate Of 93% In 69 Heavily Pretreated RANO-HGG Evaluable Patients In Pediatric Low-Grade Glioma Trial
Portfolio Pulse from Charles Gross
Day One Biopharmaceuticals' shares are up 36% premarket after the company announced a 67% overall response rate and 93% clinical benefit rate in a pediatric low-grade glioma trial involving 69 heavily pretreated RANO-HGG evaluable patients.
June 05, 2023 | 9:25 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Day One Biopharmaceuticals' stock price is up 36% premarket after announcing positive results in a pediatric low-grade glioma trial.
The positive results from the pediatric low-grade glioma trial indicate that Day One Biopharmaceuticals' treatment is effective in heavily pretreated RANO-HGG evaluable patients. This news is likely to boost investor confidence in the company's potential, leading to an increase in the stock price in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100